Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECLARE cardiovascular outcomes trial of dapagliflozin in type 2 diabetes
NL-OMON45088Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin plus background therapy with Placebo plus background therapy (2 arms). Primary endpoints: Primary efficacy endpoint, Non-inferiority assessment and 2 more. Started Aug 2013; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON45088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45088.